Update on CONTACT-02 Phase III Trial in Metastatic Castration-Resistant Prostate Cancer

Sunday, 15 September 2024, 05:45

Ipsen provides an update on the CONTACT-02 Phase III trial, investigating Cabometyx® (cabozantinib) in metastatic castration-resistant prostate cancer. The trial shows a positive trend in overall survival. Despite this, it did not meet all primary endpoints as anticipated. This results highlights ongoing challenges in treatment of advanced prostate cancer.
LivaRava_Medicine_Default.png
Update on CONTACT-02 Phase III Trial in Metastatic Castration-Resistant Prostate Cancer

CONTACT-02 Trial Overview

The CONTACT-02 trial represents a significant effort to explore new treatment combinations for metastatic castration-resistant prostate cancer. With Cabometyx® (cabozantinib) used in combination with atezolizumab, researchers aimed to address the complexities of managing this challenging cancer type.

Trial Results

  • The trial demonstrated a positive trend towards improved overall survival.
  • Although one of the primary endpoints was not fully met, the findings provide valuable insight.
  • This underscores the need for continued research and innovation in prostate cancer treatments.

Implications for Future Research

The findings from the CONTACT-02 trial will inform future studies aimed at enhancing treatment strategies for advanced stages of prostate cancer. Understanding the interactions between drugs like Cabometyx® and immune therapies could pave the way for more effective management approaches.


This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.


Related posts


Newsletter

Subscribe to our newsletter for the most accurate and current medical news. Stay updated and deepen your understanding of medical advancements effortlessly.

Subscribe